Investigation into Capricor Therapeutics
Faruqi & Faruqi, LLP, a prominent national law firm specializing in securities litigation, is currently conducting an investigation into potential legal claims on behalf of investors affected by Capricor Therapeutics, Inc. (NASDAQ: CAPR). Investors who have experienced financial losses in Capricor from leading cell therapies are especially encouraged to engage in discussions regarding their options.
Legal Rights for Investors
If you purchased or acquired securities in Capricor during the specified timeframe and faced losses, now is the time to take action. You may contact Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310) to learn more about your legal rights and discuss your circumstances further. The firm has a dedicated team that excels in providing assistance to individuals seeking to understand their legal standing.
Background on Capricor Therapeutics
The company is recognized for its innovative approaches in developing therapies for severe medical conditions, particularly for patients suffering from Duchenne muscular dystrophy (DMD). However, recent announcements have raised significant concerns regarding their lead drug candidate, deramiocel.
The Allegations Against Capricor
Faruqi & Faruqi's investigation centers on claims alleging that Capricor and its executives may have violated federal securities laws through misleading statements regarding the efficacy and approval process of their lead therapy. The company had previously suggested optimistic outcomes regarding the approval of deramiocel, only to later face setbacks from the U.S. Food and Drug Administration (FDA).
Losses Following Regulatory Disappointments
On July 11, 2025, Capricor announced it had received a Complete Response Letter (CRL) from the FDA, which denied their Biologics License Application (BLA). The CRL indicated that the application did not fulfill the statutory requirement regarding substantial evidence, and further clinical data would be required. This was a critical juncture that adversely affected investor confidence and prompted a sharp decline in stock price from $11.40 to $7.64 per share in a single day.
The Role of a Lead Plaintiff
The lead plaintiff in such cases is determined based on who has the largest financial interest in the resolution sought by the class. This individual works closely with the legal team and is a vital component of the class action process. All members of the class maintain the right to either participate as a lead plaintiff or to remain uninvolved, without any risk to their eligibility for potential recovery.
Encouragement for Whistleblowers and Insiders
Faruqi & Faruqi also urges stakeholders, including whistleblowers and former employees, to come forward with any information concerning Capricor's business practices. This information can significantly bolster the investigation and lead to a stronger case for affected investors.
Conclusion
Investors facing losses due to Capricor Therapeutics' actions have the opportunity to pursue justice through legal means. By engaging with a knowledgeable securities litigation firm, you can navigate your options effectively. Understanding your rights and acting promptly can play a critical role in potentially recovering your losses. For further inquiries or assistance, please contact the law firm directly.
Frequently Asked Questions
What are the claims against Capricor Therapeutics?
Capricor is alleged to have made false statements regarding its lead drug's approval and safety data, affecting investor trust.
Who can participate in the class action lawsuit?
Any investor who purchased Capricor securities during the specified period can join the class action and seek recourse.
How can I contact Faruqi & Faruqi for help?
You can reach out to attorney Josh Wilson at 877-247-4292 or 212-983-9330, Ext. 1310, for assistance with your case.
What happened with deramiocel?
Deramiocel's Biologics License Application was denied by the FDA, leading to significant investor losses.
What is a lead plaintiff's role?
The lead plaintiff represents the interests of all class members and directs the litigation process with the assistance of their legal counsel.
